Alnylam Pharmaceuticals Interest Expense 2011-2026 | ALNY

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Alnylam Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
5.2 M	-181 M	-126 M	-134 M	143 M	84.5 M	-	-	-3.02 M	6.17 M	76 K	1.82 M	-47 K	331 K	-531 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
143 M	-181 M	-15.6 M

Quarterly Interest Expense Alnylam Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-6.4 M	-49.7 M	-	-29.5 M	-55.7 M	-14.5 M	-	-57.7 M	-35.4 M	29 M	-	41.1 M	42.6 M	42.4 M	-	40.3 M	33.4 M	32.5 M	-	28.7 M	27.2 M	-	-	-	-	43 K	-	2.92 M	2.21 M	335 K	-	-433 K	-523 K	-2.91 M	-	401 K	229 K	5.24 M	-	-72 K	-27 K	-	-	524 K	-77 K	-82 K	-	-12 K	-11 K	5 K	-	-3 K	-21 K	191 K	-	-597 K	-16 K	81 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
42.6 M	-57.7 M	1.89 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Coherus BioSciences CHRS	9 M	$ 1.36	-4.23 %	$ 159 M	USA
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Deciphera Pharmaceuticals DCPH	16.4 M	-	-	$ 2.18 B	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Alpine Immune Sciences ALPN	98 K	-	-	$ 2.17 B	USA
ASLAN Pharmaceuticals Limited ASLN	442 K	-	-14.27 %	$ 1.7 M	Singapore
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
CRISPR Therapeutics AG CRSP	86.6 M	$ 49.44	-3.96 %	$ 4.45 B	Schweiz
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Celldex Therapeutics CLDX	927 K	$ 29.35	-0.84 %	$ 1.95 B	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	2.15 M	-	-	$ 384 M	Britain
Gracell Biotechnologies GRCL	6.74 M	-	-	$ 3.37 B	China
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 2.82	-3.09 %	$ 4.64 M	Israel
Enlivex Therapeutics Ltd. ENLV	1.93 M	$ 0.67	-2.89 %	$ 30.6 M	Israel
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	-43 K	-	-	$ 28.6 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 23.23	1.93 %	$ 2.96 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA